Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyNeena S. Abraham(National Health Laboratory Service), Nilay D. Shah(Delta Air Lines (United States))BMJApril 24, 201510.1136/bmj.h1857Cited by 345SaveCiteExport RISWatch citationsRelated PapersACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use|Circulation|2008|845